Incannex Completes Acquisition of APIRx Pharmaceuticals to Aggregate the World’s Largest Portfolio of Patented Medicinal Cannabinoid Drug Formulations

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL),
(‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal
cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs,
advises that it has finalised the acquisition of APIRx Pharmaceuticals (‘APIRx’).